Organization
Stoke Therapeutics
2 clinical trials
Clinical trial
An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet SyndromeStatus: Completed, Estimated PCD: 2023-12-13
Clinical trial
An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001Status: , Estimated PCD: 2026-02-03